- Discovery of RAF265: A Potent mut-B-RAF inhibitor for the treatment of metastatic melanoma
-
Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the treatment of pathway-dependent cancers. We report the development of imidazo-benzimidazoles as potent B-RAF inhibitors. Robust in
- Williams, Teresa E.,Subramanian, Sharadha,Verhagen, Joelle,McBride, Christopher M.,Costales, Abran,Sung, Leonard,Antonios-Mccrea, William,McKenna, Maureen,Louie, Alicia K.,Ramurthy, Savithri,Levine, Barry,Shafer, Cynthia M.,MacHajewski, Timothy,Renhowe, Paul A.,Appleton, Brent A.,Amiri, Payman,Chou, James,Stuart, Darrin,Aardalen, Kimberly,Poon, Daniel
-
p. 961 - 965
(2015/09/22)
-
- SOLID FORMS OF A RAF KINASE INHIBITOR
-
The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the sa
- -
-
-
- SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF
-
Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of { 1 -methyl-5- [2-(5-trifluoromethyl- 1 H-imidazol-2-yl)-pyridin-4-yloxy] - 1 H-benzoimidazol-2-yl } -(4- trifluoromethyl-phenyl)amine. Compositions and formulations including such
- -
-
-
- FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS
-
Formulations are provided, comprising: a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture
- -
-
Page/Page column 28-29
(2008/06/13)
-
- Substituted benzimidazoles and methods of preparation
-
Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein
- -
-
Page/Page column 20
(2008/06/13)
-